|
Market Cap (25-Jun) $12,460,301 (1,586th) |
Close (30-Jun) $0.375 |
Volume (30-Jun) 3,448 |
Shortsold (16-Aug) 1,155 (0.00%) (595th) |
|
52w High $0.79 |
52w Low $0.097 |
P/E - |
EPS -0.08 |
AGN released this announcement to the ASX on 4 October 2022, 8:01. The announcement is marked as price sensitive, and is 1 page(s) in length and 171.67kb in size.
You can view all announcements from AGN and see how they appear on a price chart on the announcements page.
At the date of this announcement, AGN was 0.000% short sold according to ASIC data. It was ranked the 653rd most shorted stock on the ASX. It is now ranked as the 595th most shorted stock on the ASX with 0.001% of total shares short sold as of the latest reported data (16 August 2024).
| Other Recent Announcements from AGN | |
|---|---|
| ARG-007 Protects Brain Cells in Moderate TBI Model | 22 June 2023, 8:19 |
| Becoming a substantial holder | 20 June 2023, 8:21 |
| Becoming a substantial holder | 13 June 2023, 17:34 |
| Argenica Receives $1.38m R&D Tax Incentive Cash Refund | 4 October 2022, 8:01 |
| Further Positive Preclinical Results for ARG-007 In HIE | 29 September 2022, 9:11 |
| Date of AGM and Closing Date for Director Nominations | 16 September 2022, 8:20 |
| Phase 1 Clinical Trial Summary | 8 September 2022, 8:34 |
You must be logged in to post a reply.
